Effect of Telmisartan on Forearm Postischemic Hyperemia and Serum Asymmetric Dimethylarginine Levels

American Journal of Hypertension

Volumn 20, Issue 12, 2007, Pages 1305-1311

  Tomiyama, Hirofumi ^a   Yamada, Jiko ^a   Koji, Yutaka ^a   Shiina, Kazuki ^a   Yoshida, Masanobu ^a   Yamashina, Akira ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

asymmetric dimethylarginine; endothelial function; Telmisartan

Indexed keywords

3 NITROTYROSINE; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CANDESARTAN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; OLMESARTAN; TELMISARTAN; VALSARTAN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOREARM; HUMAN; HYPEREMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIA; JAPAN; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARGININE; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; FEMALE; FOREARM; HUMANS; HYPEREMIA; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 36349034042     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.07.013     Document Type: Article

References (27)

1. Virdis A., Ghiadoni L., Sudano I., Buralli S., Salvetti G., Taddei S., and Salvetti A. Endothelial function in hypertension: role of gender. J Hypertens 20 Suppl (2002) S11-S16
2. Widlansky M.E., Gokce N., Keaney Jr. J.F., and Vita J.A. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42 (2003) 1149-1160
3. Muiesan M.L., Salvetti M., Monteduro C., Rizzoni D., Zulli R., Corbellini C., Brun C., and Agabiti-Rosei E. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 33 (1999) 575-580
4. Kuroda Y.T., Komamura K., Tatsumi R., Mori K., Yoneda K., Katayama Y., Shigemoto S., Miyatake K., and Hanafusa T. Vascular cell adhesion molecule-1 as a biochemical marker of left ventricular mass in the patients with hypertension. Am J Hypertens 14 (2001) 868-872
5. Tomiyama H., Kimura Y., Okazaki R., Kushiro T., Abe M., Kuwabara Y., Yoshida H., Kuwata S., Kinouchi T., and Doba N. Close relationship of abnormal glucose tolerance with endothelial dysfunction in hypertension. Hypertension 36 (2000) 245-249
6. Cooper M.E. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 17 Suppl (2004) 16S-20S
7. Janke J., Schupp M., Engeli S., Gorzelniak K., Boschmann M., Sauma L., Nystrom F.H., Jordan J., Luft F.C., and Sharma A.M. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens 24 (2006) 1809-1816
8. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
9. Blaschke F., Caglayan E., and Hsueh W.A. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. Endocrinol Metab Clin North Am 35 (2006) 561-574
10. Tomiyama H., Motobe K., Zaydun G., Koji Y., Yambe M., Arai T., Kushiro T., and Yamashina A. Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan. Am J Hypertens 18 (2005) 178-182
11. Matthews J.P., Hosker A.S., Rudenski B.A., Naylor D.F., Treacher R.C., and Turner R.C. Homeostasis model assessment insulin resistance and β-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
12. Martens-Lobenhoffer J., Krug O., and Bode-Boger S.M. Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique. J Mass Spectrom 39 (2004) 1287-1294
13. Hakansson L., Nielsen L.S., and Teder P. Measurement of neutrophil and eosinophil adhesion to E-selectin, VCAM-1, and ICAM-1 by the use of transfected fibroblast cell lines. J Immunol Methods 176 (1994) 53-66
14. Bani-Sacchi T., Bigazzi M., Bani D., Mannaioni P.F., and Masini E. Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 116 (1995) 1589-1594
15. Committee of Establishing the Definition of the Diagnosis of Metabolic Syndrome in Japan. J Jpn Soc Int Med 94 (2005) 188-203 [in Japanese]
16. Benndorf R.A., Rudolph T., Appel D., Schwedhelm E., Maas R., Schulze F., Silberhorn E., and Boger R.H. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 55 (2006) 1159-1164
17. Miura Y., Yamamoto N., Tsunekawa S., Taguchi S., Eguchi Y., Ozaki N., and Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with Type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 28 (2005) 757-758
18. Kim J.A., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
19. Sjoholm A., and Nystrom T. Endothelial inflammation in insulin resistance. Lancet 365 (2005) 610-612
20. Yano Y., Hoshide S., Ishikawa J., Noguchi C., Tukui D., Takanori H., Tada M., Kanemaru Y., Yano A., Ishikawa S., Shimada K., and Kario K. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am J Hypertens 20 (2007) 565-572
21. Boger R.H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59 (2003) 824-833
22. Shibashi T., Yoshida J., and Nishio M. New methods to evaluate endothelial function: a search for a marker of nitric oxide (NO) in vivo: re-evaluation of NOx in plasma and red blood cells and a trial to detect nitrosothiols. J Pharmacol Sci 93 (2003) 409-416
23. Yasuda S., Miyazaki S., Kanda M., Goto Y., Suzuki M., Harano Y., and Nonogi H. Intensive treatment of risk factors in patients with Type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J 27 (2006) 1159-1165
24. Tagawa T., Imaizumi T., Endo T., Shiramoto M., Harasawa Y., and Takeshita A. Role of nitric oxide in reactive hyperemia in human forearm vessels. Circulation 90 (1994) 2285-2290
25. Higashi Y., Sasaki S., Nakagawa K., Matsuura H., Kajiyama G., and Oshima T. Å "A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans". Am J Cardiol 87 (2001) 121-125
26. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
27. Wakino S., Hayashi K., Tatematsu S., Hasegawa K., Takamatsu I., Kanda T., Homma K., Yoshioka K., Sugano N., and Saruta T. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 28 (2005) 255-262